Targeted Therapy as an Alternative to Whole Brain Radiotherapy in EGFR Mutant or ALK Positive Non Small Cell Lung Cancer With Brain Metastases.
Clinical Question Is up front whole brain radiotherapy required to treat multiple brain metastases from non small cell lung cancer when highly active targeted therapies are available? Clinical Application Patients with EGFR mutant or ALK positive non small cell lung cancer with brain metastases now have the potential to achieve a prolonged survival. Through use of highly active targeted therapies, whole brain radiotherapy can be safely postponed, diminishing toxic effects that could impair quality of life.
JAMA oncology